254 related articles for article (PubMed ID: 19087987)
1. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
Roy V; LaPlant BR; Gross GG; Bane CL; Palmieri FM;
Ann Oncol; 2009 Mar; 20(3):449-53. PubMed ID: 19087987
[TBL] [Abstract][Full Text] [Related]
2. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
[TBL] [Abstract][Full Text] [Related]
3. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
4. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
Lobo C; Lopes G; Silva O; Gluck S
Biomed Pharmacother; 2007 Oct; 61(9):531-3. PubMed ID: 17913443
[TBL] [Abstract][Full Text] [Related]
7. A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
Yoshitomi S; Taira N; Doihara H; Mizoo T; Nogami T; Iwamoto T; Motoki T; Shien T; Ogasawara Y; Matsuoka J; Tsuji H; Mitsuhashi T
Cancer Chemother Pharmacol; 2016 Aug; 78(2):289-94. PubMed ID: 27316438
[TBL] [Abstract][Full Text] [Related]
8. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Lobo C; Lopes G; Baez O; Castrellon A; Ferrell A; Higgins C; Hurley E; Hurley J; Reis I; Richman S; Seo P; Silva O; Slingerland J; Tukia K; Welsh C; Glück S
Breast Cancer Res Treat; 2010 Sep; 123(2):427-35. PubMed ID: 20585851
[TBL] [Abstract][Full Text] [Related]
9. North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Moreno-Aspitia A; Perez EA
Clin Breast Cancer; 2005 Oct; 6(4):361-4. PubMed ID: 16277889
[No Abstract] [Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Ueno H; Ikeda M; Ueno M; Mizuno N; Ioka T; Omuro Y; Nakajima TE; Furuse J
Cancer Chemother Pharmacol; 2016 Mar; 77(3):595-603. PubMed ID: 26842789
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M
J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
Xu R; Yu X; Hao J; Wang L; Pan H; Han G; Xu J; Zhang Y; Yang S; Chen J; Ying J; Dai G; Li M; Begic D; Lu B; Shen L
BMC Cancer; 2017 Dec; 17(1):885. PubMed ID: 29273007
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]